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Abstract
Background: Autism spectrum disorder (ASD) affects more than 1% of children in the USA. The male-to-female
prevalence ratio of roughly 4:1 in ASD is a well-recognized but poorly understood phenomenon. An explicit focus
on potential etiologic pathways consistent with this sex difference, such as those involving prenatal androgen
exposure, may help elucidate causes of ASD. Furthermore, the multi-threshold liability model suggests that the
genetic mechanisms in females with ASD may be distinct and may modulate ASD risk in families with female ASD
in the pedigree.
Methods: We examined umbilical cord blood from 137 children in the Early Autism Risk Longitudinal Investigation
(EARLI) cohort. EARLI is an ASD-enriched risk cohort with all children having an older sibling already diagnosed with
ASD. Fetal testosterone (T), androstenedione (A4), and dehyroepiandrosterone (DHEA) levels were measured in cord
blood using liquid chromatography-tandem mass spectrometry (LC-MS/MS). Robust linear regression models were
used to determine associations between cord blood androgen levels and 12-month Autism Observation Scales for
Infants (AOSI) scores and 36-month Social Responsiveness Scale (SRS) scores adjusting for potential confounders.
Results: Increasing androgens were not associated with increasing 12-month AOSI score or 36-month total SRS
score in either boys or girls. However, the association between T and autistic traits among subjects with a female
older affected sibling was greater at 12 months (test of interaction, P = 0.008) and deficits in reciprocal social
behavior at 36 months were also greater (test of interaction, P = 0.006) than in subjects whose older affected
sibling was male.
Conclusions: While increased prenatal testosterone levels were not associated with autistic traits at 12 or
36 months, our findings of a positive association in infants whose older ASD-affected siblings were female suggests
an androgen-related mechanism that may be dependent on, or related to, genetic liability factors present more
often in families containing female ASD cases. However, this initial finding, based on a small subgroup of our
sample, should be interpreted with considerable caution.
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Background
The CDC estimates that 1 in 68 8-year-old US children
have an autism spectrum disorder (ASD) [1]. The ob-
served male-to-female prevalence ratio of approximately
4:1 in the CDC data is consistent with the vast majority
of other epidemiologic studies around the world [2].
Two of the hallmark characteristics of ASD, impaired
social interaction and communication, have been recog-
nized as traits that show sex differences in typical devel-
opment [3, 4], although debate continues around the
exact magnitude, nature, and generalizability of these
differences [5]. While this striking ASD sex difference
has long been acknowledged, the mechanisms under-
lying this difference remain largely unknown.
The nature of sex differences in cognition and behav-
ior among typically developing children has led to the
Extreme Male Brain theory of autism, which proposed
that ASD is an extreme presentation of a typical male
cognitive profile where the drive to “systemize” is stron-
ger than the drive to empathize. A mechanism involving
sex steroid exposure could be consistent with the Ex-
treme Male Brain theory [6]. Evidences from animal
research indicate that altering prenatal sex-typical ster-
oid levels can lead to permanent changes in the develop-
ing brain [7]. Androgens, especially testosterone, are
produced at higher levels in the male fetus compared to
female fetus, and androgens have an established role in
fetal brain development and are associated with sex-
related differences in behavior [3, 7, 8]. The predomin-
ant source of fetal testosterone exposure is endogenous
production by the fetal-placental unit [9] and, under
normal circumstances, only small amounts of maternal
testosterone passively diffuse across the placenta [10,
11]. In typically developing male fetuses, prenatal testos-
terone levels are higher than in female fetuses, particu-
larly between 8 and 24 weeks of gestation. There is also
a neonatal testosterone surge after birth reaching puber-
tal levels during first 3 months, which then declines to
pre-pubertal levels by 6 months of age [12].
Girls with congenital adrenal hyperplasia (CAH) are
exposed to elevated androgen concentrations and have
been studied as a model of elevated prenatal androgen
exposure in females. Girls with CAH show a more male-
typical profile compared to unaffected females in
gender-typed play across multiple studies [5, 13–15];
however, findings regarding differences in cognitive abil-
ities such as mental spatial rotation [16–18] and lan-
guage learning [18, 19] have been less consistent.
The multiple-threshold liability model explains the sex
difference in ASD prevalence as a result of females
having a higher genetic threshold for attaining ASD case
status than males and, therefore, female cases carry a
higher mutational load [20]. Two studies of high-risk
children with ASD siblings did not observe differences
in ASD recurrence by the older ASD sibling’s sex
[21, 22]. However, a large population-based dizygotic
twin pair study observed that siblings of autistic females
show greater autistic impairments than siblings of autistic
males [23], and a similar increase in average symptom
severity on the Social Responsiveness Scale among ASD
cases in families with female cases was observed in a high-
risk study of children with ASD siblings [24].
Researchers attempting to measure fetal testosterone
have assayed amniotic fluid and umbilical cord blood.
Amniotic fluid surrounding the fetus is collected via am-
niocentesis, which is generally performed between 15
and 20 weeks of gestation when the prenatal testoster-
one levels substantially differ across sexes. Amniocen-
tesis samples are limited to pregnancies with indications
for this procedure, however, which creates potential se-
lection bias if the indications for amniocentesis are asso-
ciated with outcomes under study. Moreover, the exact
relationship between steroid levels in amniotic fluid and
those in fetal circulation are not known. Umbilical cord
blood is an easily collected biological sample reflecting
late-term prenatal testosterone, available from any preg-
nancy. Testosterone levels measured in cord blood are
thought to reflect prenatal levels in late gestation after
the peak in males [25].
Several previous ASD studies have used amniotic fluid
in an attempt to determine fetal testosterone levels. Two
studies found positive associations between amniotic fluid
testosterone levels and increased autistic traits among 18–
24 month olds and 4 year olds [26, 27]; however, this was
not replicated in a recent study among 3 to 5 year olds
[28]. Another recent birth cohort-based case control study
of males found no difference in amniotic fluid testosterone
between cases and controls but observed increased amni-
otic fluid steroidogenic activity, measured as principal
components of cortisol and steroids levels along the
testosterone synthesis pathway, across cases and controls
[29]. Two published population-based studies of cord
blood testosterone level and ASD-related traits from one
group found no association [30, 31]. However, these
studies were limited by assessment of the phenotype later
in life (~20 years), and thus subjects were exposed to
decades of postnatal environmental and developmental
influences on behavior, which could influence the ability
to detect an association.
The current study aims to investigate the association
between umbilical cord blood levels of testosterone
and other related androgens and autistic traits mea-
sured at 12 months of age and social impairment
assessed at 36 months of age in the Early Autism Risk
Longitudinal Investigation (EARLI), an enriched ASD
risk pregnancy cohort. In addition, we aim to explore
whether this association was modified by the sex of
the older affected sibling.
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Methods
Description of study sample
The Early Autism Risk Longitudinal Investigation
(EARLI) is a high autism-risk cohort following pregnant
mothers with an older child diagnosed with an ASD
(autistic disorder, Asperger syndrome, or pervasive de-
velopmental disorder not otherwise specified). EARLI
families were recruited at four EARLI Network sites
(Drexel/Children’s Hospital of Philadelphia; Johns Hopkins/
Kennedy Krieger Institute; UC Davis; and Northern
California Kaiser Permanente) in three distinct US re-
gions (Southeast Pennsylvania, Northeast Maryland,
and Northern California). In addition to having a bio-
logical child with an ASD confirmed by EARLI study
clinicians, eligible mothers also had to communicate
in English or Spanish and, at recruitment, meet the
following criteria: be 18 years or older; live within
2 h of a study site; and be less than 29 weeks preg-
nant. The design of the EARLI study is described in
more detail in Newschaffer et al. [32]. Mothers were
provided with sampling kits for cord blood collection
prior to delivery. EARLI research staff made arrange-
ments with obstetricians/midwives and birth hospital
labor and delivery staff to assure proper sample collection
and temporary storage. The development of children born
into the cohort was closely followed. For this study, 212
infants born into EARLI and followed to 1 year of age
were considered for inclusion. Outcomes were autistic
traits assessed at 12 and 36 months measured by the
Autism Observation Scale for Infants (AOSI) [33] and the
Social Responsiveness Scale (SRS) [34], respectively. The
study protocol also included general neurodevelopmental
measures at these time points not analyzed here (e.g., the
Mullen Scales of Early Learning and Vineland Adaptive
Behavior Scales). Of the 212 infants, 75 were excluded
from principal analyses because they were missing either
umbilical cord blood samples or one of the two principal
outcome measures, leaving a final sample of 137 infants.
We also repeated key analyses on all available subjects
with each individual outcome who also had cord blood
available (175 subjects had AOSI-umbilical cord sample
and 140 subjects with SRS-umbilical cord sample). Demo-
graphic characteristics were similar for those included and
excluded from the study.
Laboratory methods
Testosterone (T), androstenedione (A4), and dehydro-
epiandrosterone (DHEA) and internal standards 2H3-tes-
tosterone (2H3-T) and 19-
2H3-androstenedione (
2H3-A4)
were extracted from cord blood using liquid-liquid
extraction. T, A4, DHEA, 2H3-T, and
2H3-A4 were mea-
sured using a liquid chromatography-tandem mass spec-
trometry (LC-MS/MS) assay and a calibration curve
linear across the range of the samples as previously
described (CPR Pharma Services Pty Ltd, Thebarton,
SA) [35]. Limit of quantification (LOQ) was specified as
a minimum signal-to-noise ratio of at least 5:1, with
quality controls at the LOQ successfully quantified
within 20% of its nominal concentration. The LOQ
values were 0.17, 0.35, and 3.47 nmol/L, respectively, for
T, A4, and DHEA. Distributions of T, A4, and DHEA
were all positively skewed, and loge-transformed values
were used for the analysis. Geometric mean and geometric
standard deviation were used to describe and compare the
loge-transformed androgen levels. Study characteristics
were compared across infant sex using Wilcoxon
rank-sum tests for non-normally distributed conti-
nuous variables and t tests for normally distributed
continuous variables. A χ2 test was used to test for
differences between categorical variables.
Outcome assessment
ASD-related phenotype at 12 months was assessed using
the AOSI, a semi-structured direct observational measure
that takes approximately 20 min to complete [34, 36].
There are 16 items in the AOSI that are observed in the
domains of visual tracking and attention disengagement,
coordination of eye gaze and action, imitation, affective re-
sponses, early social-communicative behaviors, behavioral
reactivity, and sensory-motor development [36]. These
items are rated on three to four point scales and summed
to generate a total score ranging from 0 to 19, with higher
scores indicating more autistic traits. Total AOSI score
has predicted subsequent ASD diagnosis in other high-
risk sibling cohort studies [37, 38]. EARLI study clinicians
engaged in regular exercises to maintain cross-site reliabil-
ity in AOSI administration.
ASD-related phenotype at 36 months was measured
using the SRS pre-school version. The SRS is a caregiver-
reported 65-item questionnaire on social awareness, so-
cial cognition, social communication, social motivation,
and autistic mannerism administered at approximately
36 months of age [39]. The SRS total raw score range
from 0 to 180 and has been used internationally in nu-
merous studies of quantitative autism traits. The SRS is a
well-established quantitative measure of traits and symp-
toms in both the general population [40] and in ASD
siblings [41] that is able to distinguish ASD children from
both non-affected children and those with other condi-
tions, such as mental retardation, with high internal
validity, reliability, and reproducibility using the estab-
lished SRS score thresholds [34, 42]. It has been vali-
dated against the “gold standard” for diagnosis, the
Autism Diagnostic Interview-Revised (ADI-R) [34, 43].
Use of the SRS in both general population and affected
samples has demonstrated that SRS scores are continu-
ously distributed and are not related to intelligence
quotient or age [34, 39, 44, 45].
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Covariates
Covariates examined included maternal characteristics
(age, education, race, ethnicity, total number of previ-
ous pregnancies), cesarean delivery, gestational age at
delivery, and sex of the older affected sibling. Potential
confounders of a priori interest were maternal age, ges-
tational age, and cesarean delivery, all of which have
been associated with both prenatal androgen level and
ASD risk [35, 46–48]. Bivariate analyses were con-
ducted between covariates and both outcomes as well
as between covariates and exposure. Candidate covari-
ates were not included in final adjusted models if they
were not associated with both the outcome and expos-
ure at a significance level of 0.1. Since we hypothesized
that other biological differences between males and
females could modify the association between testoster-
one levels and autistic traits, infant sex was examined
as a potential effect modifier. Further, since genomic
analyses suggest that multiplex families with affected
females in the pedigree may have different genetic
liability mechanisms than families with only male cases
[23], the older sibling’s sex was also explored as a
potential effect modifier.
Statistical analyses
Separate robust linear regression models [49] were
used to estimate the associations between each an-
drogen level and the two principal outcome mea-
sures. Total AOSI scores were positively skewed, and
loge (ln)-transformed (AOSI + 1) values were used to
account for subjects with zero AOSI score (n = 10,
7%). Similarly, total SRS scores were positively
skewed and loge (ln) transformation was also used.
In all analyses, androgen values below the LOQ were
replaced with estimates of the expected value of




: T = 0.12, A4 = 0.25,
DHEA = 2.45). We estimated associations between
ln(quantitative outcome) and ln(hormone concentra-
tion) in both unadjusted models and in sex-stratified
models controlling for maternal age and gestational
age. In models exploring effect modification by older
sibling sex, infant sex was also included as a covari-
ate. We also explored likelihood-based estimation (in
R) and multiple imputation by chained equations (in
SAS) approaches for handling LOQ, but in all in-
stances, results were consistent with those based on
simple replacement.
All analyses, except those noted above, were per-
formed using STATA 12 [50]. This study was approved
by the Drexel University Institutional Review Board
(IRB) and informed consent was obtained from all par-
ticipants and/or their parent/guardian in accordance
with the Drexel University IRB approved protocol.
Results
Androgens and autism phenotype in boys versus girls
Overall and sex-stratified characteristics of the infant
study sample (75 males, 62 females) are shown in
Table 1. There were no observed differences in maternal
age, education, race, ethnicity, total number of previous
pregnancies, proportion of births from cesarean sections,
or in the sex distribution of the older ASD-affected
sibling by infant sex. Among the 137 cord blood samples
analyzed, testosterone (T), androstenedione (A4), and
dehyroepiandrosterone (DHEA) measured below the
limits of quantification (LOQ) in 11, 1 and 14% of the
samples, respectively (Table 2). Female infants had a
higher proportion of T measuring below LOQ, and males
had a higher proportion of DHEA measuring below LOQ
(Table 2). Median values for T, A4, and DHEA were 0.44,
1.74, and 6.93 nmol/L, respectively (Table 2). All three an-
drogens (T, A4, and DHEA) were positively correlated
with each other, with the highest observed Pearson corre-
lations in females being 0.69 between ln-T and ln-DHEA
and the highest observed correlation in males being
0.60 between ln-A4 and ln-DHEA (Additional file 1:
Figure S1). Levels of T were on average higher (P < 0.0001)
in males (median = 0.61 nmol/L; interquartile range
(IQR) = 0.40–0.79 nmol/L) versus females (median =
0.33 nmol/L; IQR = 0.21–0.48 nmol/L) (Table 2). Levels of
A4 were similar in males and females (P = 0.23). Levels of
DHEA were on average higher (P < 0.001) in females (me-
dian = 8.75 nmol/L; IQR = 5.99–11.58 nmol/L) compared
to males (median = 5.85 nmol/L; IQR = 4.12–9.64 nmol/L)
(Table 2).
Male infants had similar (P = 0.45) geometric mean
AOSI score at 12 months (geometric mean (GM) = 5.2,
geometric standard deviation (GSD) = 2.3) compared to
females (GM = 4.7; GSD = 2.0), whereas the geometric
mean 36-month SRS score was higher (P = 0.03) in males
(GM = 33.4, GSD = 2.1) than in females (GM = 26.1,
GSD = 1.7) (Table 1 and Fig. 1). Transformed 12-month
AOSI and 36-month SRS were weakly correlated with
Pearson’s r of 0.20, with observed correlations greater
among males (r = 0.32) than females (r = 0.01).
Pearson correlations of ln-transformed androgens (T,
A4, and DHEA) and AOSI were weak (r = 0.14, 0.04, and
0.03, respectively) and remained weak within sex (males:
r = 0.13, 0.05, and 0.02, respectively; females: r = 0.11,
−0.01, and 0.1, respectively). Pearson correlations of ln-
transformed androgens (T, A4, and DHEA) and SRS
score were also weak (r = 0.10, −0.12, and −0.08, respect-
ively) and remained weak within sex (males: r = 0.05,
−0.15, and −0.01, respectively; females: r = −0.06, −0.15,
and −0.07, respectively). Figure 2 shows a sex-stratified
scatterplot of cord blood T levels against AOSI and SRS
scores. Scatterplots for A4 and DHEA are included in
Additional file 1: Figures S2–S5.
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Associations of androgen levels and autism phenotype
Unadjusted robust linear regression models did not indi-
cate any statistically significant associations between
androgen levels and autism-related phenotype at either
12 or 36 months in infants of either sex (Table 3), and
adjustment for maternal and gestational age did not alter
these findings substantively (Table 4).
Robust regression models stratifying by sex of the
older ASD-affected sibling and adjusting for maternal
and gestational age as well as infant sex, suggested that
the association between T and ASD-related phenotype at
both 12 and 36 months was stronger in those with a
female affected older sibling, and non-stratified models
incorporating interaction terms indicated that the inter-
action effects are statistically significant (Table 5). The
stratified log-log models predict that in children with a
female ASD-affected older sibling, a 25% increase in T is
associated with a 23% increase in 12-month AOSI score
(1.250.91 = 1.23), while in children with a male ASD-
affected older sibling the same increase in T is associ-
ated with just a 2% increase in 12-month AOSI score
(1.250.08 = 1.02). For 36-month SRS, this same 25% in-
crease in T among children with a female ASD-affected
older sibling is associated with a 15% increase in SRS
score (1.250.61 = 1.15), while in children with a male
ASD-affected older sibling, a 2% decrease in SRS score
(1.25−0.08 = 0.98) is predicted. For A4 and DHEA, the
patterns of associations across subgroups defined by
older affected sibling sex were similar, but the interac-
tions were not statistically significant. Figure 3 shows
the older ASD-affected sibling sex-stratified scatterplots
of cord blood T levels against 12-month AOSI and
Table 1 Study characteristics by infant sex
Total (n = 137) Female (n = 62) Male (n = 75)
Characteristics Mean SD Mean SD Mean SD P
Maternal age 34.1 4.5 33.7 4.2 34.5 4.7 0.30
Gestational age at delivery 39.4 1.6 39.4 1.4 39.3 1.7 0.68
Total number of pregnancies 3.6 1.5 3.5 1.4 3.7 1.5 0.65
Total AOSI scorea 5.0 4.3 4.7 2.0 5.2 2.3 0.45
Total SRS raw scorea 29.8 26.1 1.7 33.4 2.1 0.03
% n % n % n
Cesarean section 42.2 97 45.2 42 40 55 0.61
Maternal education 137 62 75 0.68
<9th 2.9 4.8 1.3
High school graduation 8.0 8.1 8.0
College degree 63.5 62.9 64.0
Graduate/professional degree 25.6 24.2 26.7
Maternal race 131 61 70 0.58
Asian 6.8 6.6 7.1
Black 9.2 11.5 7.1
Other 11.5 13.1 10.1
White 64.9 59.0 70
Unknown 7.6 9.8 5.7
Maternal Hispanic/Latino 19.4 129 15.2 59 22.9 70 0.27
Male older affected sibling 83.9 137 85.5 62 82.7 75 0.66
aGeometric mean and geometric standard deviation
Table 2 Testosterone (T), androstenedione (A4), and
dehydroepiandrostenedione (DHEA) levels (nmol/L) in umbilical
cord samples
Infant sexa Androgens % <LOQ Median IQR
Total (n = 137) T 11 0.44 0.12–0.64
A4 1 1.74 1.42–2.27
DHEA 14 6.93 4.72–10.89
Female (n = 62) T 19 0.33 0.21–0.48
A4 2 1.76 1.32–2.27
DHEA 8 8.75 5.99–11.58
Male (n = 75) T 4 0.61 0.40–0.79
A4 1 1.74 1.48–2.33
DHEA 19 5.85 4.12–9.64
T: P < 0.0001, A4: P = 0.23, and DHEA: P < 0.001
LOQ limit of quantification, IQR interquartile range
aTest of sex difference of geometric mean using t test
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36-month SRS scores (scatterplots for A4 and DHEA
are included as Additional file 1: Figures S6–S9).
Additional file 1 includes results, presented in a com-
parable format to Tables 4 and 5, of models adding
those subjects with only one available outcome meas-
ure (Additional file 1: Table S1). Results were similar
in magnitude and direction to those in Tables 4 and
5, and the interaction between cord blood testos-
terone level and older affected sibling sex remained
statistically significant for both outcomes (Additional
file 1: Tables S2 and S3).
Discussion
We investigated the association between prenatal andro-
gen exposure and autism-related quantitative pheno-
types among infant siblings of older children previously
diagnosed with ASD. Androgens were not associated
with autistic traits at 12 months of age within each sex.
Male infants showed significantly higher umbilical cord
testosterone levels and greater social deficits at 36 months
of age; however, elevated umbilical cord testosterone level
was not associated with social impairments after adjusting
for confounders in the full sample or in infants of either
sex. These findings are consistent with previous reports
on early adulthood autistic traits and cord blood testoster-
one level and testosterone to estrogen ratio in the general
population [30, 31] but differed from some studies on
early childhood autistic traits and testosterone in mid-
gestation amniotic fluid samples [26, 27], which was not
replicated in a recent study [51]. Our findings also suggest
that the association between androgen levels and autistic
traits may depend on sex of the older affected sibling with
a positive association observed among infants with an
older female affected sibling, after adjustment for infant
sex as well as gestational and maternal age. This pattern
of heterogeneity of effect by sex of the older affected
sibling observed at 12 months persisted in analyses with
36-month outcomes.
While these findings of effect modification by older
sibling sex must be considered as preliminary and need
to be replicated, they are consistent with some prior
findings suggesting that distinct etiologic mechanisms
may be involved in multiplex families with female af-
fected children. The empirical investigations published
to date in multiplex ASD families have examined the
influence of older affected sibling sex on recurrence risk,
and two recent analysis reported higher recurrence rates
in the next-born child when at least one of the previ-
ously affected children was female [24, 52]. This is con-
sistent with an earlier report on two large samples of
siblings of ASD-affected children that found higher
levels of quantitative ASD phenotype in younger siblings
of female probands than in younger siblings of male
probands [23]. However, two large population-based
studies [22, 53] and two smaller prospective studies of
infant siblings of ASD-affected children [21, 54] found
no differences in recurrence rates by older sibling sex.
Assuming multi-threshold liability, the model most
commonly hypothesized to explain the sex difference in
ASD prevalence, females have a higher genetic threshold
for attaining ASD case status than males and, therefore,
female cases carry a higher mutational load [20]. If some
of these mutations are also related to androgen pathways,
then these androgen-dependent mechanisms might be
more commonly involved in families with affected fe-
males. To date, there have been more than ten genes asso-
ciated with both autism and autism-related phenotype
that are also associated with some aspect of sex steroid
function (i.e., synthesis [55], transport [55], metabolism
[55, 56], or feedback mechanism [57]). In addition, genetic
variants might also modulate the susceptibility of the
developing brain to endogenous testosterone. For ex-
ample, there are two known polymorphisms in the andro-
gen receptor gene (AR), located on the X chromosome
[58], and, in one of these, the repeat sequence length has
been inversely associated with receptor transcription
activity [59, 60]. Shorter variants in this polymorphism
have been linked to higher in vitro androgen receptor
Fig. 1 Distribution of 12- and 36-month outcomes by sex.
a Twelve-month Autism Observation Scales for Infants (AOSI)
total score (n = 137, female = 62, male = 75). b Thirty-six-month
Social Responsiveness Scale (SRS) total raw score (n = 137,
female = 62, male = 75)
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Fig. 2 Relationship between umbilical cord testosterone level and 12- and 36-month outcomes by sex. a Twelve-month Autism Observation
Scales for Infants (AOSI) total score; line fit to unadjusted log-log model; infant male (circle) and female (triangle) (n = 137, female = 62, male = 75).
b Thirty-six-month Social Responsiveness Scale (SRS) total raw score; line fit to unadjusted log-log model; infant male (circle) and female (triangle)
(n = 137, female = 62, male = 75)
Table 3 Unadjusted regression models of androgen levels and 12- and 36-month outcomes within each sex
Androgensa Infant sex Outcomes
12-month AOSI 36-month SRS
Beta 95% CI P Beta 95% CI P
ln(T) Female (n = 62) 0.20 (−0.12,0.51) 0.22 −0.06 (−0.30,0.19) 0.64
Male (n = 75) 0.20 (−0.13,0.52) 0.23 0.05 (−0.25,0.36) 0.73
ln(A4) Female (n = 62) 0.06 (−0.36,0.48) 0.78 −0.18 (−0.50,0.14) 0.26
Male (n = 75) 0.06 (−0.33,0.45) 0.76 −0.21 (−0.57,0.15) 0.24
ln(DHEA) Female (n = 62) 0.09 (−0.19,0.37) 0.51 −0.05 (−0.25,0.16) 0.67
Male (n = 75) 0.04 (−0.28,0.34) 0.82 −0.01 (−0.31,0.29) 0.94
ln natural log transformed
aSeparate robust regression models of loge-transformed testosterone (T), androstenedione (A4), and dehydroepiandrostenedione (DHEA) with total loge (AOSI + 1)
and loge (SRS raw) scores. Outcome measures are 12-month Autism Observation Scales for Infants (AOSI) total score and 36-month Social Responsiveness Scale
(SRS) total raw score
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transcription activity in a kidney fibroblast cell line [59]
and were more prevalent in ASD female cases compared
to controls [60]. A recent study also indicated that some
of the genes involved in naturally occurring sexually di-
morphic processes are upregulated in ASD postmortem
brains [61].
In further considering the results here, there are also a
number of other issues and limitations. First, although
we analyzed levels of three androgens separately, given
the correlation between androgens and what is known
about steroidogenesis, the specificity of individual hor-
mone effects is not certain. Further, the current study
relied on cord blood rather than amniotic fluid samples
to evaluate androgen levels. These samples reflect late
gestation androgen levels and do not capture exposure
during the window where testosterone is higher in male
fetuses than female fetuses, particularly from weeks 8 to
24 of gestation. Amniocentesis samples, however, are
collected around the time of the large male-to-female
prenatal testosterone level difference. If this sex differ-
ence in testosterone level was critical to brain changes
influencing ASD-related behavior, then umbilical cord
measurement of androgens would be weaker in testing
hypotheses related to prenatal androgen exposure and
ASD and could have contributed to our null result.
While it has been assumed that the prenatal testosterone
level difference is critical to testosterone’s influence on
brain development, studies in nonhuman primates [62]
show that levels of fetal testosterone later in pregnancy
still independently influence sex-associated behaviors,
and research in sheep [63] has identified late pregnancy
windows where fetal testosterone influences structural
and organizational changes in the brain [64]. Consequently,
there may be multiple periods when the developing brain is
susceptible to the influence of testosterone [64, 65].
Another potential limitation of the use of cord blood
samples to measure androgens is that this sample com-
monly includes a mix of arterial and venous blood. While
androgens in the umbilical artery primarily reflect circulat-
ing fetal androgens from fetal adrenal and gonad, those in
the umbilical vein also reflect maternal and placental an-
drogens [66]. However, a recent study comparing umbilical
Table 4 Total and infant sex-stratified adjusted models of androgen levels and 12- and 36-month outcomes
Androgensa Subject sex Outcomes
12-month AOSI 36-month SRS
Beta 95% CI P Pb Beta 95% CI P Pb
ln(T) Female (n = 62) 0.20 (−0.13,0.53) 0.22 0.95 −0.05 (−0.31,0.20) 0.67 0.85
Male (n = 75) 0.22 (−0.13,0.57) 0.22 0.14 (−0.19,0.46) 0.41
ln(A4) Female (n = 62) 0.11 (−0.35,0.57) 0.64 0.90 −0.19 (−0.54,0.15) 0.27 0.89
Male (n = 75) 0.05 (−0.37,0.47) 0.81 −0.17 (−0.55,0.21) 0.38
ln(DHEA) Female (n = 62) 0.1 (−0.18,0.39) 0.48 0.74 −0.04 (−0.26,0.17) 0.70 0.84
Male (n = 75) 0.02 (−0.31,0.36) 0.88 −0.01 (−0.31,0.32) 0.97
ln natural log transformed
aRobust regression models of loge-transformed testosterone (T), androstenedione (A4), and dehydroepiandrostenedione (DHEA) with total loge (AOSI + 1) and loge
(SRS raw) adjusted for gestational age and maternal age. Outcome measures are 12-month Autism Observation Scales for Infants (AOSI) total score and 36-month
Social Responsiveness Scale (SRS) total raw score
bInteraction P value comes from a model including both subject sexes including covariates, hormone variable, and subject sex hormone interaction
Table 5 Adjusted models of androgen levels and 12- and 36-month outcomes stratified by the older affected sibling’s sex
Androgensa Older affected sibling’s sex Outcomes
12-month AOSI 36-month SRS
Beta 95% CI P Pb Beta 95% CI P Pb
ln(T) Female (n = 22) 0.91 (0.20,1.63) 0.02 0.008 0.61 (0.27,0.94) 0.001 0.006
Male (n = 115) 0.08 (−0.16, 0.32) 0.50 −0.08 (−0.30,0.14) 0.47
ln(A4) Female (n = 22) 0.22 (−1.88,2.33) 0.82 0.84 1.10 (−0.07,2.28) 0.06 0.06
Male (n = 115) 0.05 (−0.22,0.33) 0.70 −0.23 (−0.48,0.02) 0.07
ln(DHEA) Female (n = 22) 0.39 (−0.40,1.18) 0.32 0.36 0.18 (−0.26,0.61) 0.40 0.68
Male (n = 115) 0.02 (−0.20,0.24) 0.86 −0.06 (−0.26,0.14) 0.57
ln natural log transformed
aRobust regression models of loge-transformed testosterone (T), androstenedione (A4), and dehydroepiandrostenedione (DHEA) with total loge (AOSI + 1) and loge
(SRS raw) adjusted for infant sex, gestational age and maternal age. Outcome measures are 12-month Autism Observation Scales for Infants (AOSI) total score and
36-month Social Responsiveness Scale (SRS) total raw score
bInteraction P value comes from a model including both subject sexes including covariates, hormone variable, subject sex, older affected sibling sex and older
affected sibling sex hormone interaction
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artery versus umbilical vein androgen levels found that
while there are absolute differences between them, they are
highly correlated (r = 0.67 ~ 0.83) [67]. Further, a recent
population-based study of children of mothers with poly-
cystic ovarian syndrome, which has hyperandrogenism as a
defining characteristic, showed an elevated risk of autism in
the child, suggesting that maternal prenatal androgen may
also play a role in ASD risk [68].
In addition to androgen measurement issues, outcome
measurement also deserves further reflection. Our find-
ings were based on quantitative measures of ASD-related
phenotype at 12 and 36 months, not categorical diagnostic
classifications. However, twin studies have shown that the
estimated magnitudes of genetic and non-shared environ-
mental etiologic influences are quite similar regardless of
whether outcome is a dichotomous or continuous ASD-
related phenotype measure [69, 70]. This supports the idea
that continuous and dichotomous ASD outcome mea-
sures are caused by common mechanisms.
We also must be mindful that the sample size here
was modest, limiting the precision of effect estimates. In
addition, the sample included only 22 subjects who had
female older affected siblings and, therefore, the interest-
ing results pertaining to this group, though statistically
significant, are quite imprecise and this imprecision in-
creases the plausibility that these results could be a chance
finding. Lastly, as with most observational analyses, we
cannot rule out the possibility that our findings may be in-
fluenced by residual confounding despite adjusting for
known factors associated with exposure and outcome.
Conclusions
We found that increased umbilical cord blood testosterone
concentrations were not associated with autism-related
phenotype at 12 or 36 months of age in a cohort of siblings
of children with ASD. However, the existence of a positive
association in the infants whose older affected siblings were
female suggests an androgen-related mechanism that may
be dependent on, or related to, genetic liability factors
present more often in families containing female ASD
cases. The number of subjects in our sample with older fe-
male affected siblings was small, and there was no a priori
evidence supporting this particular sex-dependent mechan-
ism, so these initial results should be interpreted cautiously.
Fig. 3 Scatterplot of testosterone level and 12- and 36-month outcomes by sex of the older ASD-affected child. a 12-month Autism Observation
Scales for Infants (AOSI) total score; line fit to unadjusted log-log model (n = 137, female older affected sibling = 22, male older affected
sibling = 115). b Thirty-six-month Social Responsiveness Scale (SRS) total raw score; line fit to unadjusted log-log model (n = 137, female
older affected sibling = 22, male older affected sibling = 115)
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